Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pleural adhesion describes the formation of fibrous connective tissue bands between the parietal and visceral pleural surfaces, typically following inflammation, infection (such as tuberculous pleurisy or malignancy), trauma, or surgical intervention. Clinically, they are detected radiologically or intraoperatively and can restrict lung movement, contribute to persistent pneumothorax, and complicate thoracic surgery. They are a pathological outcome, not a discrete molecular or cellular therapeutic target and do not correspond to a canonical molecule, protein, receptor, or gene. Pleural adhesion should not be treated as a druggable target or molecular entity; instead, it is a structural result of disease or intervention and is associated with clinical management challenges rather than molecular biology.
Not applicable. Drugs like sclerosing agents induce local inflammation and fibrosis to create pleural adhesions as a therapeutic intervention.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pleural adhesion.